Igea Med
18/11/2020
On 18 December 2020, Igea Med S.p.A. obtained admission to negotiate ordinary shares on AIM Italia, a multilateral negotiations system organized and managed by Borsa Italiana. Negotiations began on 22 December 2020.
Integrae SIM acted as Nomad and Global Coordinator.
The equivalent of the placement of a total of 259,000 shares and at the start date of the negotiations on AIM Italia PRO, the share capital of Igeamed S.p.A. will be represented by a total of 2,259,000 ordinary shares with a float of 11.47% for a planned capitalization equal to € 3,388,500.
The enterprise. Igeamed, a company of the Igeam Group, operates in the market of medicine for companies and provides companies with integrated consulting and engineering services for risk management and human resources. Igeamed, which operates entirely in Italy through a capillary structure with four operational headquarters throughout the country and, in particular, in Bari, Rome, Ravenna, and Milan, aims to promote corporate healthcare, representing the ideal partner to address the new needs of companies increasingly oriented towards social responsibility and the overall well-being of employees and the company system as a whole.
Ultima Ricerca Igea Med
BREAKING NEWS| IIn the press release dated January 5th, 2026, Casta Diva Group SpA, a multinational company listed on Euronext Growth Milan and operating in the communication, branded content production and live entertainment sectors, announced the completion of the acquisition of Prodea Group SpA’s Events branch through Nautilus 6 Srl, a company wholly owned by Casta Diva Group. The acquisition, carried out within the framework of a negotiated crisis settlement procedure and subject to prior authorisation by the Court of Turin, was structured so as to transfer exclusively the “healthy” operating perimeter of Prodea, allowing the industrial asset to be isolated from the financial difficulties of the selling company. Specifically, the scope of the transaction includes goodwill, active commercial contracts, ongoing orders and the transfer of 13 employees, including managers Marco Cicchetti and Fanny Stefanetto. All of Prodea’s existing debts and liabilities were expressly excluded, enabling Casta Diva Group to acquire solely the profitable and operating component of the business. The purchase price, paid entirely at closing, amounted to € 3.00 million, against an Enterprise Value of € 3.35 million, determined net of approximately € 0.35 million relating to severance indemnities and accrued holiday and leave provisions of the transferred personnel. From a strategic standpoint, the integration of Prodea’s Events branch allows Casta Diva Group to further strengthen its positioning in live communication, expanding its client base without significant overlaps and improving its territorial presence in the Turin area, where the Group had historically been less established. The historical financial performance of the acquired business confirms the industrial rationale of the transaction: in 2024, the acquired perimeter generated revenues of € 11.90 million and an EBITDA of € 2.20 million, highlighting a solid level of profitability. This economic profile makes the transaction consistent with the selective external growth strategy already outlined in the update as of June 30th, 2025, which reiterated the Group’s objective of combining growth, margins and financial risk control. Furthermore, in the press releases dated November 25th and December 19th, 2025, Casta Diva Group announced, respectively, the launch and completion of a cash capital increase reserved for its reference shareholder Reload SpA and key figures of the Group, approved by the Board of Directors under the partial exercise of the delegation granted by the Shareholders’ Meeting held on June 29th, 2021. The transaction was necessary to strengthen Reload SpA’s shareholding and restore the ownership structure following the redemption and cancellation of the entire stake held by inheritance by the heirs of a significant Reload shareholder who passed away in November, and the subsequent entry into the Group’s share capital of institutional investors Alkemia Capital (on behalf of the “PIPE” fund) and Hoop Club, which decided to invest in Casta Diva Group’s growth potential and actively support its path of organic and external expansion. The capital increase involved the issuance of 620,000 newly issued multiple-voting shares with no nominal value, for a total consideration of € 0.97 million, including share premium. The issue price was set at € 1.56 per share, calculated based on the weighted average of CDG’s closing prices over the three months preceding the resolution of November 25th, and its fairness was confirmed by the report of the auditing firm BDO Italia SpA. The subscription was completed in full on December 19th, 2025, confirming the commitment of the main shareholders and top management to support the Group’s growth trajectory. In particular, Reload SpA increased its stake by 358,450 shares, Harbinger Srl by 159,000 shares, while Guido Palladini and Davide Rizzi subscribed for 64,500 and 38,050 shares, respectively. From a strategic perspective, the reserved capital increase serves a dual purpose: on the one hand, to retain management by aligning their interests with those of shareholders over the long term; on the other hand, to support the Group’s growth strategy, based on international expansion, the development of higher value-added content, the strengthening of live communication activities and the continuation of a selective M&A strategy. Pending further information on the allocation of the proceeds from the capital increase and further details on the integration of Prodea’s Events division, current estimates consider the capital increase exclusively as an increase in liquidity, with no changes to the business plan in terms of the use of these resources. In light of this, the update of the estimates is temporarily postponed. Taking into account the information disclosed in the aforementioned press releases, we confirm our recommendation: target price € 3.20, rating BUY, risk Medium. |
